Related Experiment Videos
Blood products and parvovirus B19.
K Groeneveld1, J van der Noordaa
1Health Council of The Netherlands, PO Box 16052, 2500 BB The Hague, The Netherlands k.groeneveld@gr.nl
The Netherlands Journal of Medicine
|August 15, 2003
Summary
The Health Council recommends testing blood products for parvovirus B19 (B19). Risk groups like pregnant women and immunocompromised patients should receive
Area of Science:
- Transfusion Medicine
- Virology
- Public Health Policy
Background:
- Parvovirus B19 (B19) infections pose minimal risk to the general population.
- However, B19 can cause severe complications in specific risk groups, including pregnant women, individuals with hematological disorders, and those with immunodeficiency.
Purpose of the Study:
- To provide recommendations on introducing parvovirus B19 (B19) testing for blood products.
- To establish safety criteria for cellular and plasma blood products concerning B19.
Main Methods:
- A risk-group approach is recommended for cellular blood products.
- 'Big-virus safe' cellular products, defined by specific antibody detection criteria, should be administered to at-risk individuals.
- For plasma products, a maximum permissible limit of 10^4 genome copies of B19 per ml in plasma pools is proposed.
Main Results:
- Cellular blood products for at-risk groups should be 'Big-virus safe', requiring IgG antibodies against B19 in two samples taken at least six months apart.
- Patients not in risk groups can continue to receive blood products meeting current safety standards.
- Plasma pools should adhere to a limit of 10^4 B19 genome copies/ml.
Conclusions:
- Implementing B19 testing in blood products is crucial for protecting vulnerable populations.
- Differentiated safety strategies for cellular and plasma products are necessary to mitigate B19 transmission risks.
- The proposed measures aim to enhance the safety of blood transfusions against parvovirus B19.